Cardinal Health's August 2025 acquisition of Solaris Health from Lee Equity for $1.9 billion added one of the largest urology platforms in America to Cardinal's specialty distribution infrastructure. The transaction followed Cardinal's 2024 acquisition of GI Alliance for $2.8B and its previous investments in Urology America and Potomac Urology. Across a compressed timeline, Cardinal built one of the most aggressive specialty-physician acquisition strategies among pharmaceutical distributors in the United States, and notably absent from Cardinal's specialty acquisition portfolio is ophthalmology. Cardinal Health hasn't publicly explained its specialty selection logic, but the pattern of acquisitions reveals it clearly. Understanding why pharmaceutical distributors like Cardinal are aggressively acquiring urology, gastroenterology, and oncology while declining to pursue ophthalmology tells capital allocators something specific about where the ophthalmology opportunity actually sits in 2026.

What Cardinal Bought and Why

Cardinal Health is the second-largest pharmaceutical distributor in the United States, with annual revenue above $200B. Its core business is the physical distribution of pharmaceuticals, medical products, and specialty medications across thousands of hospitals, clinics, and pharmacies, and the business model depends on volume, density, and integration with high-prescription-drug-utilization customer verticals. Cardinal's specialty acquisition strategy follows directly from that core business logic: the specialties Cardinal has pursued aggressively are specialties where drug acquisition, distribution, and specialty pharmacy economics are primary drivers of practice-level revenue.

Gastroenterology is drug-heavy. Biologics for inflammatory bowel disease (Humira, Stelara, Entyvio, Skyrizi, Rinvoq) run $50,000-80,000 per patient per year, and proton pump inhibitors, motility agents, and specialty GI drugs add substantial additional pharmaceutical volume per patient. The GI Alliance acquisition provided the distribution infrastructure to capture those drug economics at scale across 800+ gastroenterologists. Urology is drug-heavy in specific high-revenue sub-categories: prostate cancer treatment drugs (Xtandi, Erleada, Nubeqa, Provenge), overactive bladder medications, testosterone replacement therapy, and specialty urologic oncology drugs generate significant specialty pharmacy volume, and the Solaris Health platform brought 2,000+ providers across urology subspecialties in multiple states into Cardinal's reach. Oncology is the largest drug economics category in American medicine, with chemotherapy, targeted therapies, immunotherapies, and supportive care drugs generating more revenue per patient than any other specialty category, and Cardinal's Navista platform (oncology practice management and distribution infrastructure) reflects the same integration logic applied at even larger scale.

The common thread is that Cardinal acquires specialties where physician practices are significant downstream customers of Cardinal's core pharmaceutical distribution business. Vertical integration into physician practices captures margin across the drug economics value chain and defends Cardinal's distribution business against competing pharmacy-benefit-manager or specialty pharmacy encroachment.

Why Ophthalmology Doesn't Fit the Pattern

Ophthalmology's drug economics are substantial, but the structure is different in ways that reduce the vertical integration value for a pharmaceutical distributor like Cardinal. Retina is the most drug-heavy subspecialty within ophthalmology, with anti-VEGF injections (Lucentis, Eylea, Vabysmo, Avastin) and newer drugs like Syfovre and Izervay driving hundreds of thousands of dollars per patient-year in high-utilization cases. Retina drug economics already have a highly concentrated acquirer: Cencora, through the Retina Consultants of America acquisition at $4.4B in January 2025, captured the largest retina platform in America. Cencora is McKesson and Cardinal's primary competitor in pharmaceutical distribution, and Cardinal entering retina now would mean pursuing a smaller-scale platform in a category where Cencora has already captured the dominant position.

Non-retina ophthalmology (cataract, glaucoma, cornea, oculoplastics, refractive) generates significantly less drug revenue per patient than retina, gastroenterology, or urology. Cataract surgery is procedure-dominant rather than drug-dominant, glaucoma treatment increasingly trends toward MIGS procedures and selective laser trabeculoplasty rather than chronic drug therapy, cornea and refractive are surgical specialties with modest pharmaceutical adjuncts, and oculoplastics is procedural with cosmetic and reconstructive components that don't generate substantial specialty pharmacy volume. The result is direct: outside of retina, ophthalmology's drug economics don't match the vertical integration thesis that justifies Cardinal's acquisitions in gastroenterology and urology, and the acquisition math doesn't produce the same pharmaceutical distribution upside.

This is consistent with the broader pattern of pharmaceutical distributor specialty acquisitions. Cencora went deep in retina because retina is the drug-heavy segment of ophthalmology. McKesson acquired PRISM Vision (anterior segment and general ophthalmology) at a more modest $850M in April 2025, which reflects PRISM's lower drug economics relative to RCA, and neither Cencora nor McKesson is pursuing broad anterior segment ophthalmology consolidation the way Cardinal is pursuing urology or GI.

The Opportunity That Creates

For capital evaluating physician-led healthcare acquisition strategies, Cardinal's specialty selection logic reveals something important about where pharmaceutical distributor competition will and won't be concentrated in 2026 and beyond. Strategic corporate acquirers in ophthalmology are concentrated in retina (Cencora) and anterior segment trophy assets (McKesson), and they are not structurally positioned to pursue consolidation across the long tail of independent cataract, glaucoma, cornea, refractive, and oculoplastics practices. The drug economics don't justify the acquisition and integration cost structure for sub-$10 million transactions in those subspecialties.

The roughly 4,300 independent ophthalmology practices approaching succession in the next 36-60 months are substantially unaffected by pharmaceutical distributor competition. Cencora has what it wants in retina, McKesson has its anterior segment position, and Cardinal chose urology, gastroenterology, and oncology over ophthalmology because Cardinal's pharmaceutical distribution business doesn't benefit from anterior segment ophthalmology consolidation the way it benefits from urology and GI consolidation. The absence of aggressive pharmaceutical distributor competition in anterior segment ophthalmology creates structural room for other capital classes to operate. Patient capital operators running permanent-hold platforms don't compete with Cencora or McKesson for retina assets (both because Cencora and McKesson have already captured the leading platforms and because retina's drug economics fit pharmaceutical distributor vertical integration in ways that patient capital can't match), but in cataract, glaucoma, cornea, oculoplastics, and refractive, which represent the majority of independent ophthalmology practices by count, patient capital faces a structural opportunity where strategic corporate acquirers aren't competing aggressively.

The Broader Pattern

Cardinal's choice to deploy nearly $2B on urology instead of ophthalmology reflects a broader principle that applies across specialty physician services consolidation. Strategic corporate acquirers pursue specialties where their core business logic benefits from vertical integration, and specialties where the vertical integration math doesn't work, they skip. Pharmaceutical distributors (Cencora, McKesson, Cardinal) pursue drug-heavy specialties and skip procedure-dominant specialties where drug economics are modest. Health insurance payers (UnitedHealth/Optum, Humana/CenterWell, Elevance, CVS/Aetna) pursue specialties with high-cost utilization patterns where capitated or value-based care arrangements generate underwriting gains, and skip specialties where fee-for-service economics dominate and capitated arrangements are harder to structure. Hospital systems pursue specialties that generate inpatient volume and specialty referrals into hospital-based care, and skip specialties that are predominantly ambulatory and don't drive hospital admissions.

Ophthalmology fits none of those strategic corporate acquisition theses cleanly outside of retina. Anterior segment ophthalmology sits in a structural gap: not attractive to pharmaceutical distributors at sub-$10M transaction scale, not structured for payer acquisition, not valued by hospital systems. That structural gap is the opportunity for capital that's positioned differently than pharmaceutical distributors, payers, or hospital systems. Patient capital that values stable cash flow, demographic-tailwind-driven volume growth, ASC economics, and multi-decade physician ownership arcs finds attractive economics in exactly the ophthalmology subspecialties that strategic corporate acquirers are skipping.

Cardinal Health bought a major urology platform because Cardinal's business benefits from vertical integration in urology. Cardinal didn't buy an ophthalmology platform because Cardinal's business doesn't benefit from vertical integration in ophthalmology, which leaves ophthalmology available to a different capital class altogether. For capital positioned to operate in that gap, the implication is direct: the specialty that pharmaceutical distributors aren't pursuing aggressively, that payers can't structure capitated economics around, and that hospital systems never prioritized is the specialty with the most structural room for patient-capital operator-led consolidation over the next decade. Cardinal's specialty choice is a data point, but the underlying logic applies to every pharmaceutical distributor and every strategic corporate acquirer evaluating American physician services. The specialty they consistently deprioritize creates the opportunity for the capital class they don't compete with.

Educational material only. Figures are illustrative and individual results vary. Images are AI-generated illustrations and do not depict actual Verdira practices, physicians, or patients. See our Disclosures.